The main molecular changes that can be targeted in NSCLC for today are EGFR mutation, ALK translocation and ROS1 translocation. Previous studies on the predictive role of 18F-FDG PET/CT for EGFR mutations in patients with NSCLC are conflicting. The aim of this study was to evaluate the relationship between FDG uptake changes, genetic mutation status and clinical parameters of patients diagnosed with NSCLC in our clinic retrospectively and to investigate whether 18F-FDG PET are valuable in predicting EGFR mutations, ALK and ROS-1 rearrangement.
